Sanofi And Regeneron Initiate 400-Patient Coronavirus Trial With Kevzara
The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.
Coronavirus Update: South Korea's Celltrion Progresses Antibody, Yancopoulos: 'The World Is Counting On Us'
Regeneron's head of R&D George Yancopoulos delivers some stirring words about the need to unify against the global threat posed by COVID-19.